PubMed | Weifang Peoples Hospital Weifang, Shanghai JiaoTong University, Xi'an Jiaotong University, Jinan Military General Hospital Jinan and Dalian Medical University
Type: Journal Article | Journal: Thoracic cancer | Year: 2015
Kirsten rat sarcoma (KRAS) mutations are widespread in lung adenocarcinoma patients. The combined utilization of KRAS antisense oligodeoxynucleotide (ASODN) and insulin-like growth factor-I receptor (IGF-IR) may inhibit the proliferation of A549 cell lines of lung adenocarcinoma.Point mutations of the KRAS gene in A549 cells were detected by polymerase chain reaction with special sequence primers (PCR-SSP) and gene sequence analysis; ASODN was designed and synthesized according to the mutation specialty of KRAS; and the correlation of gene mutations and clinicopathological features were analyzed. Inhibition on the proliferation and morphostructure change were measured by methyl thiazolyl tetrazolium and colony-forming unit assays. Flow cytometry was used to evaluate the expression of KRAS and IGF-IR proteins and cell apoptosis and reverse transcriptase-polymerase chain reaction were used to detect the expression of KRAS and IGF-IR messenger ribonucleic acid (mRNA). Male nude mice were used to form the mice-human lung cancer model and show the inhibition of KRAS ASODN on A549 cells.PCR-SSP and gene sequence analysis results showed that the codon 12 of KRAS had changed from GGT to GTT. KRAS ASODN or IGF-IR ASODN could inhibit cell proliferation and promote apoptosis of A549 cells. However, the combined utilization of KRAS ASODN and IGF-IR ASODN could inhibit cell proliferation and promote apoptosis more powerfully than exclusive use of KRAS ASODN or IGF-IR ASODN.The two ASODNs can inhibit the proliferation of lung adenocarcinoma cells through decreasing the expression of KRAS and IGF-IR mRNA and protein.
PubMed | Harbin Medical University and Jinan Military General Hospital Jinan
Type: Journal Article | Journal: International journal of clinical and experimental medicine | Year: 2014
This study aimed to investigate the effects of Dexmedetomidine combined with Dezocine on the cognition and hippocampal microglia activation of rats.Laparotomy was successfully performed in 48 rats which were then divided into Dexmedetomidine+Dezocine group and Dezocine group. Rats in Dexmedetomidine+dezocine group were infused with Dexmedetomidine and dezocine via the tail vein after anesthesia; rats in Dezocine group were infused with dezocine via the tail vein. After surgery, rats underwent detection of learning and memory functions at 1, 3, and 7 days after surgery, and the neuroglobin and norepinephrine expression was detected in the hippocampal microglia at the same time points.1, 3 and 7 days after surgery, the latency to escape in Dexmedetomidine+Dezocine group was significantly shorter than that in Dezocine group, and the number of cells positive for neuroglobin or norepinephrine in the CAL region of hippocampus of Dexmedetomidine+Dezocine group was also markedly higher than that of Dezocine group (P < 0.05).Surgery and anesthesia have influence on the cognition of rats to a certain degree, and dexmedetomidine combined with dezocine can effectively improve the impaired cognition due to surgery and anesthesia, which may be attributed to the increase in the protective neuroglobin and norepinephrine in the hippocampus.